We Analyzed the Future Direction of CRISPR Therapeutics AG (CRSP), Here is What We Found – News Heater
Home  »  Business   »  We Analyzed the Future Direction of CRISPR Therape...

We Analyzed the Future Direction of CRISPR Therapeutics AG (CRSP), Here is What We Found

CRISPR Therapeutics AG (NASDAQ:CRSP) went up by 9.44% from its latest closing price compared to the recent 1-year high of $169.76. The company’s stock price has collected -10.09% of loss in the last five trading sessions. Barron’s reported on 04/20/21 that Vertex Is Buying Majority Rights to Gene-Editing Therapy From CRISPR Therapeutics

Is It Worth Investing in CRISPR Therapeutics AG (NASDAQ :CRSP) Right Now?

CRISPR Therapeutics AG (NASDAQ:CRSP) scored a price-to-earnings ratio above its average ratio, recording 10.71 x from its present earnings ratio. Plus, the 36-month beta value for CRSP is at 2.04. Opinions of the stock are interesting as 16 analysts out of 26 who provided ratings for CRISPR Therapeutics AG declared the stock was a “buy,” while 1 rated the stock as “overweight,” 8 rated it as “hold,” and 1 as “sell.”

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .


CRSP currently public float of 76.60M and currently shorts hold a 13.56% ratio of that float. Today, the average trading volume of CRSP was 1.42M shares.

CRSP’s Market Performance

CRSP stocks went down by -10.09% for the week, with a monthly drop of -23.22% and a quarterly performance of -22.49%, while its annual performance rate touched -54.31%. The volatility ratio for the week stands at 10.55% while the volatility levels for the past 30 days are set at 7.36% for CRISPR Therapeutics AG. The simple moving average for the period of the last 20 days is -14.49% for CRSP stocks with a simple moving average of -43.83% for the last 200 days.

Analysts’ Opinion of CRSP

Many brokerage firms have already submitted their reports for CRSP stocks, with Credit Suisse repeating the rating for CRSP by listing it as a “Neutral.” The predicted price for CRSP in the upcoming period, according to Credit Suisse is $78 based on the research report published on April 28th of the current year 2022.

SVB Leerink gave a rating of “Outperform” to CRSP, setting the target price at $126 in the report published on October 19th of the previous year.

CRSP Trading at -20.78% from the 50-Day Moving Average

After a stumble in the market that brought CRSP to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -72.13% of loss for the given period.

Volatility was left at 7.36%, however, over the last 30 days, the volatility rate increased by 10.55%, as shares sank -23.01% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -22.91% lower at present.

During the last 5 trading sessions, CRSP fell by -10.09%, which changed the moving average for the period of 200-days by -60.32% in comparison to the 20-day moving average, which settled at $54.62. In addition, CRISPR Therapeutics AG saw -37.57% in overturn over a single year, with a tendency to cut further losses.

Insider Trading

Reports are indicating that there were more than several insider trading activities at CRSP starting from TOMSICEK MICHAEL JOHN, who sale 25,000 shares at the price of $138.52 back on Aug 06. After this action, TOMSICEK MICHAEL JOHN now owns 1,891 shares of CRISPR Therapeutics AG, valued at $3,462,926 using the latest closing price.

Kulkarni Samarth, the Chief Executive Officer of CRISPR Therapeutics AG, sale 28,500 shares at $128.98 during a trade that took place back on Aug 05, which means that Kulkarni Samarth is holding 187,719 shares at $3,675,939 based on the most recent closing price.

Stock Fundamentals for CRSP

Equity return is now at value 16.20, with 14.50 for asset returns.

Leave a Comment

Your email address will not be published.




Download Free eBook For


100% free. stop anytime no spam